MRVI
Price
$6.76
Change
-$0.29 (-4.11%)
Updated
Jul 24 closing price
Capitalization
997.14M
16 days until earnings call
Intraday BUY SELL Signals
NVCT
Price
$19.31
Change
-$0.84 (-4.17%)
Updated
Jul 24 closing price
Capitalization
608.76M
16 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

MRVI vs NVCT

MRVI vs NVCT Comparison Chart in %
View a ticker or compare two or three
VS
MRVI vs. NVCT commentary
Jul 26, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRVI is a Hold and NVCT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 26, 2026
Stock price -- (MRVI: $6.76 vs. NVCT: $19.31)
Brand notoriety: MRVI and NVCT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MRVI: 38% vs. NVCT: 43%
Market capitalization -- MRVI: $997.14M vs. NVCT: $608.76M
MRVI [@Biotechnology] is valued at $997.14M. NVCT’s [@Biotechnology] market capitalization is $608.76M. The market cap for tickers in the [@Biotechnology] industry ranges from $121.16B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MRVI’s FA Score shows that 1 FA rating(s) are green whileNVCT’s FA Score has 0 green FA rating(s).

  • MRVI’s FA Score: 1 green, 4 red.
  • NVCT’s FA Score: 0 green, 5 red.
According to our system of comparison, MRVI is a better buy in the long-term than NVCT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MRVI’s TA Score shows that 3 TA indicator(s) are bullish while NVCT’s TA Score has 3 bullish TA indicator(s).

  • MRVI’s TA Score: 3 bullish, 5 bearish.
  • NVCT’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, NVCT is a better buy in the short-term than MRVI.

Price Growth

MRVI (@Biotechnology) experienced а -6.63% price change this week, while NVCT (@Biotechnology) price change was +0.89% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.78%. For the same industry, the average monthly price growth was -3.76%, and the average quarterly price growth was +1901.89%.

Reported Earning Dates

MRVI is expected to report earnings on Aug 11, 2026.

NVCT is expected to report earnings on Aug 11, 2026.

Industries' Descriptions

@Biotechnology (-4.78% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MRVI($997M) has a higher market cap than NVCT($609M). NVCT YTD gains are higher at: 155.762 vs. MRVI (108.000). NVCT has higher annual earnings (EBITDA): -28.27M vs. MRVI (-104.31M). MRVI has more cash in the bank: 166M vs. NVCT (25.1M). MRVI has higher revenues than NVCT: MRVI (205M) vs NVCT (0).
MRVINVCTMRVI / NVCT
Capitalization997M609M164%
EBITDA-104.31M-28.27M369%
Gain YTD108.000155.76269%
P/E RatioN/AN/A-
Revenue205M0-
Total Cash166M25.1M661%
Total Debt271MN/A-
TECHNICAL ANALYSIS
Technical Analysis
MRVINVCT
RSI
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
74%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
88%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
87%
MACD
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 9 days ago
78%
Bullish Trend 3 days ago
89%
Declines
ODDS (%)
Bearish Trend 2 days ago
84%
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
77%
Aroon
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
MRVI
Daily Signal:
Gain/Loss:
NVCT
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CMJIX51.510.32
+0.63%
Calvert US Mid Cap Core Rspnb Idx I
JIGFX64.66N/A
N/A
Janus Henderson Overseas I
JEVAX11.80-0.09
-0.76%
JHancock Disciplined Value Em Mkts Eq A
RERCX59.22-0.68
-1.14%
American Funds EUPAC R-3
UOPIX147.47-3.47
-2.30%
ProFunds UltraNASDAQ-100 Inv